bortezomib

bortezomib

美 　英

• 网络硼替佐米；万珂；蛋白酶体抑制剂硼替佐米

例句

Results Bortezomib can be a time and dose dependent manner inhibited the growth of DC.

结果：硼替佐米能够以时间、剂量依赖方式抑制DC的生长。

Conclusion: Bortezomib alone or in combination with irinotecan was not effective in patients with relapsed or refractory CRC.

结论：单用硼替佐米或联合伊立替康对复发或耐药的结直肠癌无效。

A lot of reports suggested that bortezomib had a significant effect in treatment of multiple myeloma in out country.

国内有许多关于硼替佐米治疗多发性骨髓瘤临床疗效的研究报道指出其疗效显著。

With the application of time, bortezomib was extended continuously.

随着应用时间的延长，硼替佐米不断被推广。

The history of brought bortezomib in clinical and used it for multiple myeloma treatment is about 5 years.

我国医疗界将硼替佐米应用于临床，用于治疗多发性骨髓瘤的历史大约5年。

The hazard ratio for overall survival was 0. 61 for the bortezomib group (P=0. 008).

硼替佐米组的总生存期的危险比率为0.61（P=0.008）。

To study the effects of bortezomib on the cell adhesion and the cell adhesion mediated adriamycin resistance of RPMI8226 cells.

研究硼替佐米对黏附介导骨髓瘤细胞的阿霉素耐药逆转作用。

Salvage Therapy with Proteasome Inhibitor Bortezomib for Relapsed and Refractory Multiple Myeloma

蛋白酶体抑制剂硼酸盐二肽治疗难治性多发性骨髓瘤

The proportions of patients with a partial response or better were 71% in the bortezomib group and 35% in the control group;

部分缓解或更好反应的患者比例，硼替佐米组为71%，而对照组为35%的；

Clinical Progress on Bortezomib in the Treatment for Multiple Myeloma

硼替佐米治疗多发性骨髓瘤临床应用进展

Induction of Apoptosis in HL-60 Cells by Bortezomib alone or in Combination with Harringtonine In Vitro

硼替佐米单用或联合三尖杉酯碱体外诱导HL-60细胞凋亡实验研究